Analyst Viewpoint
Rise in prevalence of hepatitis and R&D of new therapeutics are driving the hepatitis therapeutics market size. To control and completely eradicate hepatitis infections, this market offers a range of therapeutic alternatives such as immunomodulators, antiviral medications, and vaccinations.
Growth in awareness, better diagnostics, and technological developments in medicines are also boosting the hepatitis therapeutics industry demand.
R&D of new drugs is likely to offer lucrative hepatitis therapeutics market opportunities to vendors. Vendors are focused on the development of functional cures for the treatment of chronic hepatitis.
Leading molecules under development have entered clinical evaluation for the treatment of the disease.
Hepatitis is defined by inflammation of the liver, which is typically brought on by viral infections. The term "hepatitis therapeutics" describes various approaches to manage and treat the condition.
These treatments seek to lessen liver damage and symptoms. Hepatitis treatment includes several antiviral medicines that can help fight the virus and slow its ability to damage the liver.
Entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir), adefovir (Hepsera), and telbivudine are some of the widely used hepatitis therapeutics. Tenofovir disoproxil fumarate (TDF) or entecavir (ETV) is the first-line oral therapy.
| Attribute | Detail |
|---|---|
| Drivers |
|
Hepatitis is the inflammation of the liver, primarily caused by viral infections such as hepatitis A, B, and C. Amongst all of these, Hepatitis B is a highly prevalent virus that can cause severe liver cirrhosis and is considered to be extremely lethal.
Hepatitis B is the most prevalent acute liver infection in the world and a major concern to public health, additionally, it serves as the main cause of hepatocellular carcinoma, or HCC, the most common type of liver cancer and the second largest cause of cancer-related deaths worldwide. Thus, surge in prevalence of hepatitis is augmenting the hepatitis therapeutics market development.
According to a report by the Centers for Disease Control and Prevention (CDC), around 2,045 new cases of acute hepatitis B were reported in the U.S. in 2021, and around 14,229 cases of chronic hepatitis B were newly reported in 2021.
Governments and organizations across the globe are making efforts to increase awareness regarding hepatitis and its treatment.
Additionally, some governments are launching sponsored programs to encourage patients to accept hepatitis therapeutics which can reduce the prevalence of hepatitis. Such efforts are contributing to the hepatitis therapeutics market growth.
In 2023, Virion Therapeutics dosed the first patients in a Phase Ib trial investigating VRON-0200 as a functional cure for chronic Hepatitis B virus (HBV) infection.
The first-in-human study plans to enroll 48 patients at sites in Hong Kong and New Zealand. Such trials are focusing on functional treatment for hepatitis, thereby driving the hepatitis therapeutics market expansion.
Direct-acting antiviral (DAA) medications provide a more effective and direct method for hepatitis treatment as they are specially made to target the hepatitis virus's replicating mechanism. Since DAAs precisely target the proteins needed for HCV replication, they are more effective than prior treatments that attempted to treat the virus as a whole.
This makes them particularly helpful in treating the Hepatitis C virus (HCV). DAAs are usually taken in combination with two or three other medications to address the issue of HCV becoming resistant to single-drug therapy. Development and broad acceptance of DAA medications is fueling the hepatitis therapeutics market trajectory.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest hepatitis therapeutics market trends, North America held largest share in 2022. Rise in prevalence of hepatitis, government initiatives and strategic plans for hepatitis treatment, and implementation of cutting-edge treatment approaches are propelling the market dynamics of the region.
The Viral Hepatitis National Strategy Plan: 2021–2025 was released in the U.S. with the goals of enhancing data usage and surveillance, lowering disparities and health inequities, and improving health outcomes connected to viral hepatitis.
Presence of a well-established healthcare infrastructure, advantageous reimbursement policies, and increase in investment in research and development are also driving the hepatitis therapeutics market share in North America.
The global hepatitis therapeutics market landscape is highly competitive, with several opportunities for expansion and innovation. Major players are exploring personalized medicine in hepatitis therapeutics to revolutionize treatment approaches and improve patient outcomes.
Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Bristol Myers Squibb, Merck & Co., Inc., AbbVie Inc., NATCO Pharma Limited, Zydus Cadila, Hetero Healthcare Limited, LAURUS Labs, and Cipla, Inc. are some of the key players in this market.
Each of these companies has been profiled in the hepatitis therapeutics market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 16.0 Bn |
| Market Forecast (Value) in 2031 | US$ 21.9 Bn |
| Growth Rate (CAGR) | 3.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 16.0 Bn in 2022
It is anticipated to grow at a CAGR of 3.6% from 2023 to 2031
Rise in prevalence of hepatitis and R&D of new therapeutics
North America provided higher business opportunities in 2022
Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Bristol Myers Squibb, Merck & Co., Inc., AbbVie Inc., NATCO Pharma Limited, Zydus Cadila, Hetero Healthcare Limited, LAURUS Labs and Cipla, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hepatitis Therapeutics Market Analysis and Forecast, by Disease
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease, 2017–2031
6.3.1. Hepatitis A
6.3.2. Hepatitis B
6.3.3. Hepatitis C
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease
7. Global Hepatitis Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.3.2. NS5A Inhibitor
7.3.3. Multi-class Combination
7.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.3.5. Interferon & Ribavirin
7.3.6. Others
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Hepatitis Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Drug Class
9. Global Hepatitis Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease, 2017–2031
10.3.1. Hepatitis A
10.3.2. Hepatitis B
10.3.3. Hepatitis C
10.3.4. Others
10.4. Market Value Forecast, by Drug Class, 2017–2031
10.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.4.2. NS5A Inhibitor
10.4.3. Multi-class Combination
10.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.4.5. Interferon & Ribavirin
10.4.6. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease
10.7.2. By Drug Class
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease, 2017–2031
11.3.1. Hepatitis A
11.3.2. Hepatitis B
11.3.3. Hepatitis C
11.3.4. Others
11.4. Market Value Forecast, by Drug Class, 2017–2031
11.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.4.2. NS5A Inhibitor
11.4.3. Multi-class Combination
11.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.4.5. Interferon & Ribavirin
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease
11.7.2. By Drug Class
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease, 2017–2031
12.3.1. Hepatitis A
12.3.2. Hepatitis B
12.3.3. Hepatitis C
12.3.4. Others
12.4. Market Value Forecast, by Drug Class, 2017–2031
12.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.4.2. NS5A Inhibitor
12.4.3. Multi-class Combination
12.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.4.5. Interferon & Ribavirin
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease
12.7.2. By Drug Class
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease, 2017–2031
13.3.1. Hepatitis A
13.3.2. Hepatitis B
13.3.3. Hepatitis C
13.3.4. Others
13.4. Market Value Forecast, by Drug Class, 2017–2031
13.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.4.2. NS5A Inhibitor
13.4.3. Multi-class Combination
13.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.4.5. Interferon & Ribavirin
13.4.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease
13.7.2. By Drug Class
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disease, 2017–2031
14.3.1. Hepatitis A
14.3.2. Hepatitis B
14.3.3. Hepatitis C
14.3.4. Others
14.4. Market Value Forecast, by Drug Class, 2017–2031
14.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.4.2. NS5A Inhibitor
14.4.3. Multi-class Combination
14.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.4.5. Interferon & Ribavirin
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease
14.7.2. By Drug Class
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Gilead Sciences, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. F. Hoffmann-La Roche, Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bristol Myers Squibb
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AbbVie Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. NATCO Pharma Limited
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Zydus Cadila
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Hetero Healthcare Limited
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. LAURUS Labs
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Cipla, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 02: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 03: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 07: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 08: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 11: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 15: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 16: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 19: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 20: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031
Table 23: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 24: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Hepatitis Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Disease, 2022
Figure 03: Global Hepatitis Therapeutics Market Value Share, by Disease, 2022
Figure 04: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022
Figure 05: Global Hepatitis Therapeutics Market Value Share, by Drug Class, 2022
Figure 06: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Hepatitis Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 08: Global Hepatitis Therapeutics Market Value Share, by Region, 2022
Figure 09: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 11: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2020–2031
Figure 12: Global Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 13: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2031
Figure 14: Global Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 15: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2031
Figure 16: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2020–2031
Figure 18: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 22: North America Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 23: North America Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031
Figure 25: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 26:North America Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 31: Europe Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 32: Europe Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031
Figure 34: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 35: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 40: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 41: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031
Figure 43: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 44: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 49: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 50: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031
Figure 52: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 53: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031
Figure 58: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031
Figure 59: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031
Figure 61: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 62: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hepatitis Therapeutics Market
